ライフサイエンスコーパス: avelumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 s were enrolled and initiated treatment with avelumab.

2 l patients who received at least one dose of avelumab.

3 those expressing PD-L1, after treatment with avelumab.

4 e enrolled and received at least one dose of avelumab.

5 m patients who received at least one dose of avelumab.

6 IN Solid Tumor trial) assessed four doses of avelumab (1 mg/kg, 3 mg/kg, 10 mg/kg, and 20 mg/kg), wit

7 and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks.

8 nts unselected for PD-L1 expression received avelumab (10 mg/kg, 1 h intravenous infusion) every 2 we

9 ssessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (

10 Avelumab, a human Ig-G1 monoclonal antibody targeting PD

11 Avelumab, a human monoclonal anti-PD-L1 antibody, has sh

12 We assessed treatment with avelumab, an anti-PD-L1 monoclonal antibody, in patients

13 esults Forty-four patients were treated with avelumab and followed for a median of 16.5 months (inter

14 um therapy and cisplatin-naive) treated with avelumab and to assess antitumour activity of this drug

15 ious adverse event related to treatment with avelumab, and one treatment-related death occurred (pneu

16 ts were eligible and received treatment with avelumab for a median of 12 weeks (IQR 6.0-19.7) and fol

17 INTERPRETATION: Avelumab has an acceptable toxicity profile up to 20 mg/

18 provide the rationale for therapeutic use of avelumab in metastatic urothelial carcinoma and it has r

19 establish the safety and pharmacokinetics of avelumab in patients with solid tumours while assessing

20 providing a rationale for further studies of avelumab in this disease setting.

21 Patients received infusional avelumab monotherapy 10 mg/kg every 2 weeks until diseas

22 Avelumab (MSB0010718C) is a human IgG1 monoclonal antibo

23 till ongoing, and was well tolerated; hence, avelumab represents a new therapeutic option for advance

24 INTERPRETATION: Avelumab showed an acceptable safety profile and antitum

25 INTERPRETATION: Avelumab showed antitumour activity in the treatment of

26 anageable safety profile was reported in all avelumab-treated patients.

27 se-expansion cohort of that trial, we assess avelumab treatment in a cohort of patients with advanced

28 Avelumab was associated with durable responses, most of

29 Avelumab was given as a 1-h intravenous infusion every 2

30 Avelumab was given intravenously at a dose of 10 mg/kg e

31 Conclusion Avelumab was well tolerated and associated with durable

32 ious adverse event related to treatment with avelumab, with infusion-related reaction (in four [2%] p

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。